Covenant Partners’s West Pharmaceutical WST Stock Holding History

Covenant Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-883	Closed	-$265K	–	184
2024 Q3	$265K	Hold	883	–	–	0.08%	143
2024 Q2	$291K	Hold	883	–	–	0.09%	141
2024 Q1	$349K	Hold	883	–	–	0.1%	131
2023 Q4	$311K	Sell	883 -35	-4%	-$12.4K	0.1%	139
2023 Q3	$344K	Buy	918 +35	+4%	+$13.5K	0.13%	127
2023 Q2	$338K	Hold	883	–	–	0.12%	123
2023 Q1	$306K	Sell	883 -179	-17%	-$52.3K	0.12%	133
2022 Q4	$250K	Hold	1,062	–	–	0.1%	151
2022 Q3	$261K	Hold	1,062	–	–	0.13%	141
2022 Q2	$321K	Hold	1,062	–	–	0.15%	131
2022 Q1	$436K	Sell	1,062 -189	-15%	-$74K	0.17%	114
2021 Q4	$587K	Hold	1,251	–	–	0.22%	102
2021 Q3	$531K	Hold	1,251	–	–	0.21%	103
2021 Q2	$449K	Hold	1,251	–	–	0.17%	124
2021 Q1	$353K	Hold	1,251	–	–	0.14%	144
2020 Q4	$354K	Sell	1,251 -91	-7%	-$25.5K	0.15%	130
2020 Q3	$369K	Buy	+1,342	New	+$355K	0.18%	128

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Covenant Partners's WST Position: Q4 2024 in Review

Covenant Partners sold out of West Pharmaceutical (WST) in Q4 2024, closing a stake of 883 shares — an estimated $265K sold.

Covenant Partners first reported a position in WST in Q3 2020 and held it in 17 quarters. The position peaked at $587K in Q4 2021. 748 funds tracked by Wall St. Rank hold WST as of Q4 2024.

Covenant Partners reported no remaining West Pharmaceutical position as of Q4 2024 after selling out during the quarter.
Covenant Partners sold 883 West Pharmaceutical shares in Q4 2024, an estimated $265K.
Covenant Partners first reported a position in West Pharmaceutical in Q3 2020 and held it in 17 quarters.
Covenant Partners's West Pharmaceutical position peaked at $587K in Q4 2021.
748 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2024.

Based on Covenant Partners's 13F filing for Q4 2024, filed 14 Feb 2025.